

# **HBM's Global Partnership with Pfizer Inc.**

## **Global License Agreement for HBM9033 (MSLN-Targeted ADC)**

---

**HBM HOLDINGS-B**

**02142.HK**

[www.harbourbiomed.com](http://www.harbourbiomed.com)



# Global Collaboration to Maximize the Value of Novel Therapeutics



Payments in the aggregate amount of US\$53 million upfront and near-term payments



Potential milestone payments based on certain pending development and commercial achievements of up to approximately US\$1.05 billion in aggregate



Tiered royalties on net sales up to high teens.


# HBM9033 (MSLN)

## Next-Gen Mesothelin ADC for Solid Tumors




### Highlights

- ❑ Unique fully human antibody warhead with improved binding, internalization, blocking activity and less interference by sMSLN
- ❑ The 4th generation novel payload with tumor-specific cleavable linker and high serum stability
- ❑ Superior therapeutic window compared to other ADC technologies
- ❑ **IND clearance in August 2023**




### Robust anti-tumor activities and better PK/PD profile observed in preclinical studies


Better efficacy than MMAE based ADC in mouse CDX model



Better efficacy than DXd based ADC in mouse CDX model



Confirmed in-vivo stability of ADC shows minimal payload release in monkey



# Harbour BioMed: Leader in Global Biologic Therapeutics Innovation

A Global Company  
Focusing on Breakthrough Medicines



Clinical Operations:

CN USA AUS

- Established in 2016
- Transformed into a clinical stage company in 2017
- 3 INDs in 2018
- HBM4003 entered Ph1 in 2019

- Successfully listed in HKEx in 2020
- HBM9022 globally out-licensed to AbbVie in 2020
- HBM7008 and HBM9378 IND Filing in 2021

- HBM7022 globally out-licensed to AZ
- HBM7008 collaboration with Cullinan
- HBM4003 advanced into global phase II
- HBM9378, HBM1020 advance in clinical stage
- HBM1020,1007,1022,9033 achieved US IND
- HBM9033 Globally out-licensed to Pfizer

2016-2019

2020-2021

2022-2023

Harbour Therapeutics:  
The rapid advancement of a differentiated innovative global portfolio

# Nona Biosciences Leverages Industry-leading Technology Platforms to Empower Global Therapeutic Innovation

## Clinically Validated Platforms

- **50+** industry and academic partners
- **18+** projects entered clinical stage

## Continuous Technology Innovation

- HCAb PLUS
- Bispecific Ab
- ADC / XDC
- Ab+ mRNA
- Ab+ AI

## Experienced Scientific Team


- **3** innovation centers
- **70+** experienced research scientists
- advancing **10+** FIC/BIC

## Rapid Business Growth

- new partners
- collaboration projects ongoing




## Protein Engineering




## Conjugation Technology



## Delivery Technology



## Cell Therapy Technology





# Q&A



和铂医药

扫描下方二维码，关注我的公众号



诺纳生物 Nona Biosciences

扫描下方二维码，关注我的公众号

# THANK YOU



和铂医药

扫描下方二维码，关注我的公众号



诺纳生物 Nona Biosciences

扫描下方二维码，关注我的公众号

